With a platform-enabled value proposition in drug development, our strategy is to pursue clinically validated pathways in cancer indications where we identify potential candidate compounds from research institutes, and pursue clinical success through translational research, alliance, co-development, and partnerships to create breakthrough science that meaningfully changes life of patients.
We build our pipeline to address the unmet medical needs from the growing patient population with multiple solid tumor types. Currently there are four proprietary assets that address the unmet medical needs from the growing patient population with multiple solid tumor types We have the potential to pursue both common and rare cancer driven by actional mutation and epigenetic modification and bring the treatments to a wide variety of patients.
